| RGX-111 Gene Therapy in Patients With MPS I (NCT03580083) | REGENXBIO Inc. | 2019-04-03 |
| Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (NCT03513328) | University of Florida | 2018-06-15 |
| MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis (NCT02171104) | Masonic Cancer Center, University of Minnesota | 2014-07-10 |
| Bone Marrow Transplant With Abatacept for Non-Malignant Diseases (NCT01917708) | Emory University | 2014-01-01 |
| Administration of IV Laronidase Post Bone Marrow Transplant in Hurler (NCT01173016) | Masonic Cancer Center, University of Minnesota | 2012-05-29 |
| Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome (NCT01572636) | Masonic Cancer Center, University of Minnesota | 2012-03-28 |
| Neurobehavioral Phenotypes in MPS III (NCT01873911) | University of Minnesota | 2010-12-01 |
| Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders (NCT01043640) | Masonic Cancer Center, University of Minnesota | 2009-12-01 |
| Intrathecal Enzyme Replacement for Hurler Syndrome (NCT00638547) | Masonic Cancer Center, University of Minnesota | 2008-01-02 |
| Effects of Growth Hormone in Chronically Ill Children (NCT00286689) | University of Texas Southwestern Medical Center | 2006-02-03 |
| Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease (NCT00258011) | Genzyme, a Sanofi Company | 2005-12-01 |
| Stem Cell Transplant w/Laronidase for Hurler (NCT00176891) | Masonic Cancer Center, University of Minnesota | 2004-03-01 |
| A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old (NCT00146757) | Genzyme, a Sanofi Company | 2002-10-01 |
| BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study (NCT03639844) | Bellicum Pharmaceuticals | |